###### Abstract  
Background: Species belonging to the Asteraceae family have been widely studied for their healing properties. The paper introduces STOMAPET (patent pending A2016/0088/23.11.2016) based on _Eupatorium cannabinoid_ (hemp-agrimony) and _Inula helenium_ (electampagne) and its potential application in diseases of the oral system. Methods: STOMAPET was prepared according to the patent application and HPLC analysis was performed for chemical analysis. In vitro studies were performed using human monocytes and the cells' viability was determined by MTS assay. In vivo studies involved lipopolysaccharide (LPS)-induced murine endotoxemia and veterinary clinical case reports. Results: HPLC analysis revealed various phenolic compounds and alantolactone. In in vitro studies, monocytes viability remained stable, around and above 100% at all concentrations (7.8 to 250 \(\mu\)g/mL), and a high stimulatory effect on cell proliferation was noted. In LPS-induced murine endotoxemia, STOMAPET prevents mortality, improves the decrease in body mass, and prevents the drop in temperature. Case reports of companion animals with oral diseases ameliorated after STOMAPET treatment are presented. Conclusions: Preclinical studies confirmed the safety of STOMAPET and its pharmacological potential. The results of the veterinary case reports are also encouraging. More studies are needed to find the precise mechanism of action in correlation to chemical composition.  
**Keywords:**_Inula helenium; Eupatorium cannabinoid_; periodontal disease; immunomododulation; endotoxemia +
Footnote †: journal: Applied  
and terpenes have been identified as the two main chemical constituents of _Eupatorium_[9]. It was shown both in in vitro [8; 10] and in vivo assays [6] that the antiinflammatory activity of _Eupatorium_ main compounds is exerted on the gene and protein level by down-regulation of proinflammatory mediators (CSF-3, IL-1\(\alpha\), IL-1\(\beta\), IL-6, and TNF-\(\alpha\)), chemokines (CCL2, CCL22, and CXCL10), and inhibition of nitric oxide (NO) release.  
Moreover, another genus belonging to the Asteraceae family, _Inula_, is traditionally used in Europe as a valuable source of active compounds with anti-inflammatory activity--_I. cappa_[11], _I. helenium_[12], _I. japonica_[13], etc. Sesquiterpene lactones, mainly alantolactone and isoalantolactone, are considered as its active ingredients [14]. In experimental models of inflammation, these compounds supress nitric oxide production and other proinflammatory cytokines via the downregulation of nuclear factor kappa B (NF-kB) and TNF receptor associated factor 6 (TRAF6) [15; 16; 17; 18; 19], interfere with leukotriene synthesis and phospholipase A2-induced mastocyte release of inflammatory mediators [20], stabilize lysosomal membranes, and induce an antiproliferative effect [21].  
This paper introduces STOMAPET (patent pending A2016/00888/23.11.2016) based on _Eupatorium cannabinoid_ (hemp-agrimony) and _Inula hehenium_ (electampagne) extracts and its potential as immunomododulatory agent, proved by preclinical studies. Several case reports from veterinary area demonstrated that STOMAPET could be applied successfully as healing, antiinflammatory, and antiseptic agent in diseases of the oral system.